Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4466 | eM2M Wiki | 0.50 |
| drug739 | COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support Wiki | 0.50 |
| drug4299 | Weight Counseling Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016135 | Spinal Dysraphism NIH | 0.50 |
| D002547 | Cerebral Palsy NIH | 0.29 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013119 | Spinal Cord Injuries NIH | 0.19 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.17 |
| D010300 | Parkinsonian NIH | 0.17 |
| D001930 | Brain Injuries, NIH | 0.14 |
| D009103 | Multiple Sclerosis NIH | 0.12 |
| D003920 | Diabetes Mellitus, NIH | 0.09 |
| D014947 | Wounds and Injuries NIH | 0.08 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002414 | Spina bifida HPO | 0.50 |
| HP:0001264 | Spastic diplegia HPO | 0.29 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000819 | Diabetes mellitus HPO | 0.09 |
Navigate: Correlations HPO
There are 4 clinical trials
The overarching goal of this proposal is to understand the comparative effectiveness of obesity counseling as covered by CMS in improving weight loss for adults either with or at high risk of type 2 diabetes. CMS and most insurers now include obesity screening and counseling benefits, with no cost sharing to patients. Since overweight patients are at highest risk for diabetes, improved weight management services could prevent diabetes and its negative health outcomes. Beneficiaries with obesity are eligible for up to 20 face-to-face visits for weight counseling in the primary care setting. The investigators propose comparing weight and diabetes outcomes in three states using EHR and claims data before and after this policy was implemented by leveraging the novel infrastructure of the Patient-Centered Outcomes Research Institute-funded PaTH Clinical Data Research Network. Following developments during the COVID-19 pandemic, the investigators further plan to leverage our study infrastructure across five health systems to understand the comparative effectiveness of telemedicine approaches for providing outpatient care for patients with or at risk of type 2 diabetes and how these approaches impact the subgroup of patients with COVID-19.
Description: Weight change during counseling and/or % of weight change during program and maintained over remaining time period will be assessed in both the diabetes and pre-diabetes cohorts.
Measure: Weight change Time: 10 yearsDescription: In the pre-diabetes cohort, diabetes incidence will be determined as the % of patients who develop diabetes following weight counseling. In the diabetes cohort, uncontrolled diabetes will be measured.
Measure: Diabetes Incidence Time: 10 yearsDescription: Incidence of hospitalization will be assessed for COVID-19 positive patients
Measure: Hospitalization Time: 1 yearDescription: Incidence of intubation will be assessed for COVID-19 positive patients
Measure: Intubation Time: 1 yearDescription: Incidence of death will be assessed for COVID-19 positive patients
Measure: Death Time: 1 yearThe aim of the study is to evaluate whether the therapy with chloroquine phosphate (CQ, in combination with telemedical approach) in addition to standard care is effective and safe in reducing composite endpoint of COVID-19-related hospitalization or all cause death, in ambulatory patients with SARS-SoV-2 infection at particular risk of serious complications due to advanced age and/or comorbid conditions (in comparison with subjects not treated with CQ but receiving standard care and supervised telemedically).
Description: Composite endpoint of COVID-19-related hospitalization or all-cause death
Measure: COVID-19-related hospitalization or all-cause death Time: 15 daysDescription: Decrease in self-reported symptoms of novel coronavirus infection. Non-dichotomous symptoms (e.g. syncope is dichotomous - yes or no) such as dyspnoea will be self-evaluated by patients using the 0-3 scale with the severity increasing with the punctation (0-no symptoms, 1-mild symptoms, 2-moderate symptoms, 3-severe symptoms).
Measure: Decrease in COVID-19 symptoms Time: 15 days and 42 daysDescription: Based on X-ray, microbiology and laboratory results
Measure: Development of pneumonia Time: 42 daysDescription: Acute respiratory distress syndrome, bacterial infection, shock, sepsis, etc
Measure: Development of coronavirus infection-related complications Time: 42 daysThe goal of the research is to assess candidate COVID-19 rapid diagnostic tests (e.g. immunodiagnostic tests, like Coris Bioconcept Ag Respi-strip COVID-19 test, and LAMP-based molecular tests) in order to judge their clinical accuracy compared to Centers for Disease Control (CDC)-recommended molecular genetic testing and clinical diagnosis. Second, it is our goal to determine if self-testing assisted by COVIDscanDX mobile device camera acquisition software platform and telemedicine clinical/technical support (virtual point-of-care) improves the ease of use and immediate interpretation of the tests, thus making self-testing comparable in accuracy and safety to testing in a clinical setting. The overall purpose of the study is to dramatically increase the capacity of COVID-19 testing by establishing the safety, ease-of-use and validity of self-testing assisted by mobile device imaging and telemedicine remote support.
Description: Accuracy refers to the amount of agreement between the results of the antibody-based rapid test and the results of a PCR-based reference test
Measure: Clinical accuracy of the antibody and antigen rapid tests compared to LAMP/PCR-based test result Time: 1 yearDescription: Accuracy refers to the amount of agreement between the results of the rapid tests and a clinical diagnosis of COVID-19
Measure: Clinical accuracy of the antibody and antigen rapid tests based on Clinical diagnosis Time: 1 yearDescription: Clinical accuracy of the subject's visual interpretation of the test result vs image analysis from clinician
Measure: Self-test interpretation of result vs expert clinical image interpretation of result Time: 1 yearDescription: Subjects will complete a survey to rate the testing procedure for ease of use and convenience. The survey will ask subjects to rate the ease of use on a scale from 1 (easiest procedure to complete and understand) to 10 (most complicated and confusing procedure)
Measure: Ease of self-testing procedure Time: 1 yearBackground Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. The investigators hypothesize that telemedicine (TM) can be an effective mode of health-care delivery minimizing the risk of SARS-CoV-2 exposure, while maintaining disease control in these patients. Objectives The primary aim of this study is to evaluate the effectiveness to achieve remission or lupus low disease activity state (LLDAS) using TM delivered care compared to conventional in-person outpatient follow-up in SLE. The secondary objectives are to compare the patient reported outcomes and cost between the two modes of health care delivery. Study design This is a 12-months single centered pragmatic randomized controlled study. A total of 150 enrolled patients with SLE being followed at the Prince of Wales Hospital rheumatology clinics will be randomized to either TM (TM group) or standard care (SC group) in a 1:1 ratio. Patients in the TM group will receive scheduled follow-ups via videoconferencing using a custom-made mobile app. SC group patients will continue conventional standard in-person outpatient care. The disease and patient reported outcomes as well as the health care related costs will be compared. Expected outcomes Data from this study will support the notion that TM based care is as effective as conventional in-person care in achieving disease remission or LLDAS, as well as addressing psychosocial implications to ensure the best possible care for our patients in a cost-effective manner during this pandemic.
Description: LupusQoL evaluates 8 domains including physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Questionnaire has a 5-point Likert response format (0=all the time, 1=most of the time, 2=a good bit of the time, 3=occasionally, and 4=never). Higher score means better quality of life.
Measure: The change of Lupus Quality of Life (LupusQoL) at one year. Time: 1 yearDescription: They are in a 5-point Likert response format (0=strongly disagree, 1=disagree, 2=neutral, 3=agree, and 4=strongly agree). Higher score means more confident and satisfied.
Measure: Patient confidence and satisfaction score at one year. Time: 1 yearDescription: HAQ-DI covers various common daily activities to assess disability.It consists of 8 questions. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). Higher score means higher disability.
Measure: The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year. Time: 1 yearDescription: HADS was developed to assess anxiety and depression in medical patients. Each domain has 7 items. Each item are answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. Higher score means more likely the patient has anxiety or depression.
Measure: The change of (Hospital Anxiety and Depression Scale) HADS at one year. Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports